Evaro, a leading UK-based digital health startup providing AI-powered clinical and drug prescription services, today announced it has secured its Care Quality Commission (CQC) registration.

Evaro was founded by Dr. Thuria Wenbar and Dr. Oskar Wenbar after realising that 25% of A&E consultations and 40% of GP appointments were dealing with minor health conditions. The company has been offering online pharmacy services regulated by the General Pharmaceutical Council (GPhC) since September 2018. 

The addition of CQC registration allows Evaro to expand beyond medication dispensing to offer more comprehensive healthcare services, including medical diagnosis through asynchronous consultations reviewed by registered clinicians. This expansion is particularly timely given the NHS's current challenges, where long delays have led to thousands of unnecessary deaths.

Under this new registration, Evaro can deliver a more robust and comprehensive service for patients through its ecosystem of brands aimed at meeting patients at various points in their healthcare journey:

• Evaro: The company can enable its brand partners such as travel, beauty or lifestyle brands, to offer similar comprehensive healthcare services to their customers.
• e-Surgery: Evaro's flagship patient facing brand can now initiate treatments, offer a wider range of diagnoses, and provide blood testing services directly to patients.
• e-Pharmacy: This brand will continue to service NHS prescriptions, allowing patients across the country to receive their NHS prescriptions online for free.

Across these platforms, Evaro will provide improved ongoing care and support through a multidisciplinary team of clinicians, offering a wider range of treatments and diagnostic capabilities - and building a better healthcare infrastructure for the digital age.

Dr. Thuria Wenbar, CEO and co-founder of Evaro, commented: "Securing our CQC registration is a pivotal moment for Evaro and a testament to our commitment to patient safety and quality care. This not only validates our approach to digital healthcare but also sets us apart in the industry. Unlike many online pharmacies who do not have it, our CQC registration allows us to function as a full doctor service, request blood tests, interpret test results and make new diagnoses. We can now offer a full spectrum of care - from initial diagnosis through to treatment. This capability, combined with our AI-driven platform and NHS integration, will be crucial in our mission to serve 10 million people and address the growing healthcare access issues in the UK. ”

The CQC registration requires excellence in safety, effectiveness, caring, responsiveness, and leadership. Evaro underwent rigorous evaluation, to prove adherence to these standards. Evaro is one of few organisations to achieve this registration, highlighting its commitment to quality and patient-centric digital healthcare.

Evaro will complement its medical services with lifestyle coaching and diagnostic offerings. This includes exercise and nutrition coaching where NICE guidance recommends it, as well as blood tests and pathology services through a partnership with Doctors Laboratory Limited. 

As part of this process, Evaro appointed a new Registered Manager, Dr. Michael Brooks, an experienced A&E doctor and CEO of PatientSource, a platform used by major hospitals in the UK and overseas for handling electronic patient records.

Dr. Brooks added, "Our market research showed that patients want more than just a transactional experience. They want a person-centred, safe, and transparent service that is medically led to support their individual health needs. The months of preparation, documentation, and scrutiny associated with getting the CQC registration will have been worth it because we can now do exactly this. Improving patient access to consultation and treatment for minor health issues such as acne, migraines, contraception, menopause, will also reduce the burden on NHS GPs as they can use their time and resources for more concerning health issues”. 

To enhance its healthcare services, Evaro also leverages AI models which are trained on extensive research conducted by expert clinicians, and which allow the company to provide asynchronous consultations and private prescription medication at scale - integrating self-service questionnaires and robust clinical safety checks. This achievement comes on the heels of Evaro's recent $1.5 million seed funding round, a growing user base of over 600,000 patients, and partnerships signed with prominent consumer brands.